The prolactin receptor as a therapeutic target in human diseases: Browsing new potential indications

Expert Opinion on Therapeutic Targets

Volumn 19, Issue 9, 2015, Pages 1229-1244

  Goffin, Vincent ^a   Touraine, Philippe ^b  

^a INSERM   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

Antagonists; antibodies; atherosclerosis; autoimmunity; cancer; hair; hyperplasia; inflammation; pain; Stat5; targeted therapy; tumorigenesis

Indexed keywords

DOPAMINE RECEPTOR STIMULATING AGENT; FINASTERIDE; MESSENGER RNA; MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; ORAL CONTRACEPTIVE AGENT; PROLACTIN; PROLACTIN RECEPTOR; PROLACTIN RECEPTOR ANTAGONIST; PROTEIN INHIBITOR; STAT5 PROTEIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ACUTE MYELOBLASTIC LEUKEMIA; ADENOMYOSIS; AUTOIMMUNE DISEASE; BREAST CANCER; BREAST DISEASE; DIGESTIVE SYSTEM CANCER; DOPAMINERGIC NERVE CELL; DRUG RECEPTOR BINDING; ENDOMETRIOSIS; ENDOMETRIUM CANCER; HAIR LOSS; HUMAN; HYPERPROLACTINEMIA; LYMPHANGIOLEIOMYOMATOSIS; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVARY CANCER; POSTOPERATIVE PAIN; PROLACTINOMA; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATITIS; PROTEIN EXPRESSION; PSORIASIS; REVIEW; SIGNAL TRANSDUCTION; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; ANTAGONISTS AND INHIBITORS; BREAST NEOPLASMS; DRUG DESIGN; FEMALE; MALE; METABOLISM; PATHOLOGY; PROSTATIC NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG DESIGN; FEMALE; HUMANS; MALE; MOLECULAR TARGETED THERAPY; PROLACTIN; PROSTATIC NEOPLASMS; RECEPTORS, PROLACTIN;

EID: 84940040626     PISSN: 14728222     EISSN: 17447631     Source Type: Journal    
DOI: 10.1517/14728222.2015.1053209     Document Type: Review

References (107)

1. Bole-Feysot C, Goffin V, Edery M, et al. Prolactin and its receptor: actions, signal transduction pathways and phenotypes observed in prolactin receptor knockout mice. Endocr Rev 1998; 19: 225-68
2. Ormandy CJ, Camus A, Barra J, et al. Null mutation of the prolactin receptor gene produces multiple reproductive defects in the mouse. Genes Dev 1997; 11: 167-78
3. Newey PJ, Gorvin CM, Cleland SJ, et al. Mutant prolactin receptor and familial hyperprolactinemia. N Engl J Med 2013; 369: 2012-20
4. Damiano JS, Wasserman E. Molecular pathways: blockade of the PRLR signaling pathway as a novel antihormonal approach for the treatment of breast and prostate cancer. Clin Cancer Res 2013; 19: 1644-50
5. Clevenger CV, Furth PA, Hankinson SE, Schuler LA. The role of prolactin in mammary carcinoma. Endocr Rev 2003; 24: 1-27
6. Goffin V, Bernichtein S, Touraine P, Kelly PA. Development and potential clinical uses of human prolactin receptor antagonists. Endocr Rev 2005; 26: 400-22
7. Brooks CL. Molecular mechanisms of prolactin and its receptor. Endocr Rev 2012; 33: 504-25
8. Tallet E, Fernandez I, Zhang C, et al. Investigation of prolactin receptor activation and blockade using time-resolved fluorescence resonance energy transfer. Front Endocrin 2011; 2: 29
9. Brooks A.J, Dai W, OMara ML, et al. Mechanism of activation of protein kinase JAK2 by the growth hormone receptor. Science 2014; 344: 1249783
10. Marano RJ, Ben Jonathan N. Minireview: extrapituitary prolactin: an update on the distribution, regulation, and functions. Mol Endocrinol 2014; 28: 622-33
11. Newbern D, Freemark M. Placental hormones and the control of maternal metabolism and fetal growth. Curr Opin Endocrinol Diabetes Obes 2011; 18: 409-16
12. Freeman ME, Kanyicska B, Lerant A, Nagy G. Prolactin: structure, function, and regulation of secretion. Physiol Rev 2000; 80: 1523-631
13. Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev 2006; 27: 485-534
14. Ma FY, Anderson GM, Gunn TD, et al. Prolactin Specifically Activates STAT5b in Neuroendocrine Dopaminergic Neurons. Endocrinology 2005; 146: 5112-19
15. Goffin V, Kinet S, Ferrag F, et al. Antagonistic properties of human prolactin analogs that show paradoxical agonistic activity in the Nb2 bioassay. J Biol Chem 1996; 271: 16573-9
16. Bernichtein S, Kayser C, Dillner K, et al. Development of pure prolactin receptor antagonists. J Biol Chem 2003; 278: 35988-99
17. Goffin V, Tallet E, Jomain JB, Kelly PA. Development of Prolactin Receptor Antagonists: Same Goal, Different Ways. Rec Pat Endocr Metab Immune Drug Discov 2007; 1: 41-52
18. Walker AM. S179D prolactin: antagonistic agony!. Mol Cell Endocrinol 2007; 276: 1-9
19. Liu Y, Gong W, Breinholt J, et al. Discovery of the improved antagonistic prolactin variants by library screening. Protein Eng Des Sel 2011; 24: 855-60
20. Langenheim JF, Chen WY. Improving the pharmacokinetics/pharmacodynamics of prolactin, GH, and their antagonists by fusion to a synthetic albumin-binding peptide. J Endocrinol 2009; 203: 375-87
21. Kopchick JJ, Parkinson C, Stevens EC, Trainer PJ. Growth hormone receptor antagonists: discovery, development, and use in patients with acromegaly. Endocr Rev 2002; 23: 623-46
22. Damiano JS, Rendahl KG, Karim C, et al. Neutralization of prolactin receptor function by monoclonal antibody LFA102, a novel potential therapeutic for the treatment of breast cancer. Mol Cancer Ther 2013; 12: 295-305
23. Freiberg C, Otto C, Linden L, et al. Neutralizing prolactin receptor antibody mat3 and its therapeutic use. WO2012163932A1; 2012
24. Jacobson EM, Hugo ER, Tuttle TR, et al. Unexploited therapies in breast and prostate cancer: blockade of the prolactin receptor. Trends Endocrinol Metab 2010; 21: 691-8
25. Tworoger SS, Eliassen AH, Zhang X, et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res 2013; 73: 4810-19
26. Berinder K, Akre O, Granath F, Hulting AL. Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur J Endocrinol 2011; 165: 209-15
27. Ferraris J, Bernichtein S, Pisera D, Goffin V. Use of prolactin receptor antagonist to better understand prolactin regulation of pituitary homeostasis. Neuroendocrinology 2013; 98: 171-9
28. Utama FE, Tran TH, Ryder A, et al. Insensitivity of human prolactin receptors to nonhuman prolactins: relevance for experimental modeling of prolactin receptor-expressing human cells. Endocrinology 2009; 150: 1782-90
29. Nitze L.M, Galsgaard E.D, Din N, et al. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. Breast Cancer Res Treat 2013; 142: 31-44
30. Christensen HR, Murawsky MK, Horseman ND, et al. Completely humanizing prolactin rescues infertility in prolactin knockout mice and leads to human prolactin expression in extrapituitary mouse tissues. Endocrinology 2013; 154 (12): 4777-89
31. Idelman G, Jacobson EM, Tuttle TR, Ben Jonathan N. Lactogens and estrogens in breast cancer chemoresistance. Expert Rev Endocrinol Metab 2011; 6: 411-22
32. Arendt LM, Schuler LA. Transgenic models to study actions of prolactin in mammary neoplasia. J Mammary Gland Biol Neoplasia 2008; 13: 29-40
33. Peck AR, Witkiewicz AK, Liu C, et al. Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol 2011; 29: 2448-58
34. Nouhi Z, Chughtai N, Hartley S, et al. Defining the role of prolactin as an invasion suppressor hormone in breast cancer cells. Cancer Res 2006; 66: 1824-32
35. Sultan AS, Xie J, LeBaron MJ, et al. Stat5 promotes homotypic adhesion and inhibits invasive characteristics of human breast cancer cells. Oncogene 2005; 24: 746-60
36. Barcus CE, Holt EC, Keely PJ, et al. Dense collagen-I matrices enhance pro-tumorigenic estrogen-prolactin crosstalk in MCF-7 and T47D breast cancer cells. PLoS One 2015; 10: e0116891
37. Wagner KU, Rui H. Jak2/Stat5 signaling in mammogenesis, breast cancer initiation and progression. J Mammary Gland Biol Neoplasia 2008; 13: 93-103
38. Levina VV, Nolen B, Su Y, et al. Biological significance of prolactin in gynecologic cancers. Cancer Res 2009; 69: 5226-33
39. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci USA 2005; 102: 7677-82
40. Lopez-Pulido EI, Munoz-Valle JF, Toro-Arreola S, et al. High expression of prolactin receptor is associated with cell survival in cervical cancer cells. Cancer Cell Int 2013; 13: 103
41. Asai-Sato M, Nagashima Y, Miyagi E, et al. Prolactin inhibits apoptosis of ovarian carcinoma cells induced by serum starvation or cisplatin treatment. Int J Cancer 2005; 115: 539-44
42. Tan D, Chen KE, Khoo T, Walker AM. Prolactin increases survival and migration of ovarian cancer cells: importance of prolactin receptor type and therapeutic potential of S179D and G129R receptor antagonists. Cancer Lett 2011; 310: 101-8
43. Wen Y, Zand B, Ozpolat B, et al. Antagonism of tumoral prolactin receptor promotes autophagy-related cell death. Cell Rep 2014; 7: 488-500
44. Courtillot C, Plu-Bureau G, Binart N, et al. Benign breast diseases. J Mammary Gland Biol Neoplasia 2005; 10: 325-35
45. Bogorad RL, Courtillot C, Mestayer C, et al. Identification of a gain-of-function mutation of the prolactin receptor in women with benign breast tumors. Proc Natl Acad Sci USA 2008; 105: 14533-8
46. Bilibio JP, Souza CA, Rodini GP, et al. Serum prolactin and CA-125 levels as biomarkers of peritoneal endometriosis. Gynecol Obstet Invest 2014; 78: 45-52
47. Martinez LB, Leyva MZ, Romero IC. Prolactin receptor in human endometriotic tissues. Acta Obstet Gynecol Scand 2002; 81: 5-10
48. Lidegaard O, Nielsen LH, Skovlund CW, et al. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011; 343: d6423
49. Stattin P, Rinaldi S, Stenman UH, et al. Plasma prolactin and prostate cancer risk: A prospective study. Int J Cancer 2001; 92: 463-5
50. Sackmann-Sala L, Goffin V. Prolactin-induced prostate tumorigenesis. Adv Exp Med Biol 2015; 846: 221-42
51. Ahonen TJ, Harkonen PL, Rui H, Nevalainen MT. PRL signal transduction in the epithelial compartment of rat prostate maintained as long-term organ cultures in vitro. Endocrinology 2002; 143: 228-38
52. Tan SH, Dagvadorj A, Shen F, et al. Transcription factor Stat5 synergizes with androgen receptor in prostate cancer cells. Cancer Res 2008; 68: 236-48
53. Thomas LN, Morehouse TJ, Too CK. Testosterone and prolactin increase carboxypeptidase-D and nitric oxide levels to promote survival of prostate cancer cells. Prostate 2012; 72: 450-60
54. Thomas LN, Merrimen J, Bell DG, et al. Carboxypeptidase-D is elevated in prostate cancer and its anti-apoptotic activity is abolished by combined androgen and prolactin receptor targeting. Prostate 2014; 74: 732-42
55. Rouet V, Bogorad RL, Kayser C, et al. Local prolactin is a target to prevent expansion of basal/stem cells in prostate tumors. Proc Natl Acad Sci USA 2010; 107: 15199-204
56. Sackmann-Sala L, Chiche A, Mosquera-Garrote N, et al. Prolactin-induced prostate tumorigenesis links sustained stat5 signaling with the amplification of basal/stem cells and emergence of putative luminal progenitors. Am J Pathol 2014; 184: 3105-19
57. Goldstein AS, Huang J, Guo C, et al. Identification of a cell of origin for human prostate cancer. Science 2010; 329: 568-71
58. Kindblom J, Dillner K, Ling C, et al. Progressive prostate hyperplasia in adult prolactin transgenic mice is not dependent on elevated serum androgen levels. Prostate 2002; 53: 24-33
59. Van Coppenolle F, Slomianny C, Carpentier F, et al. Effects of hyperprolactinemia on rat prostate growth: evidence of androgeno-dependence. Am J Physiol Endocrinol Metab 2001; 280: E120-9
60. Wennbo H, Kindblom J, Isaksson OG, Tornell J. Transgenic mice overexpressing the prolactin gene develop dramatic enlargement of the prostate gland. Endocrinology 1997; 138: 4410-15
61. Kindblom J, Dillner K, Sahlin L, et al. Prostate hyperplasia in a transgenic mouse with prostate-specific expression of prolactin. Endocrinology 2003; 144: 2269-78
62. Bernichtein S, Pigat N, Camparo P, et al. Anti-inflammatory properties of Lipidosterolic extract of Serenoa repens (Permixon®) in a mouse model of prostate hyperplasia. Prostate 2015; 75: 706-22
63. Lai KP, Huang CK, Fang LY, et al. Targeting stromal androgen receptor suppresses prolactin-driven benign prostatic hyperplasia (BPH). Mol Endocrinol 2013; 27: 1617-31
64. Syms AJ, Harper ME, Griffiths K. The effect of prolactin on human BPH epithelial cell proliferation. Prostate 1985; 6: 145-53
65. Leav I, Merk FB, Lee KF, et al. Prolactin receptor expression in the developing human prostate and in hyperplastic, dysplastic, and neoplastic lesions. Am J Pathol 1999; 154: 863-70
66. Galsgaard ED, Rasmussen BB, Folkesson CG, et al. Re-evaluation of the prolactin receptor expression in human breast cancer. J Endocrinol 2009; 201: 115-28
67. Rannikko S, Adlercreutz H. Plasma estradiol, free testosterone, sex hormone binding globulin binding capacity, and prolactin in benign prostatic hyperplasia and prostatic cancer. Prostate 1983; 4: 223-9
68. Colao A, Vitale G, Di Sarno A, et al. Prolactin and prostate hypertrophy: a pilot observational, prospective, case-control study in men with prolactinoma. J Clin Endocrinol Metab 2004; 89: 2770-5
69. McPherson SJ, Wang H, Jones ME, et al. Elevated androgens and prolactin in aromatase-deficient mice cause enlargement, but not malignancy, of the prostate gland. Endocrinology 2001; 142: 2458-67
70. Yatkin E, Bernoulli J, Talvitie EM, Santti R. Inflammation and epithelial alterations in rat prostate: impact of the androgen to oestrogen ratio. Int J Androl 2009; 32: 399-410
71. Lobie PE, Garcia-Aragon J, Waters MJ. Prolactin receptor expression in the gastrointestinal tract: characterization of the prolactin receptor of gastric mucosa. J Endocrinol 1993; 139: 371-82
72. Nagano M, Chastre E, Choquet A, et al. Expression of prolactin and growth hormone receptor genes and their isoforms in the gastrointestinal tract. Am J Physiol 1995; 268: G431-42
73. Bhatavdekar JM, Patel DD, Vora HH, et al. Prolactin as a local growth promoter in patients with locally advanced tongue cancer: GCRI experience. Head Neck 2000; 22: 257-64
74. Chauhan A, Kurian J, Kakria A, et al. Prognostic value of prolactin in postoperative colorectal carcinoma. Gastrointest Cancer Res 2008; 2: 260-1
75. Neradugomma NK, Subramaniam D, Tawfik O, et al. Prolactin induces Notch signaling in a Jak2-STAT and Jak2-ERK pathways in colon cancer stem and progenitor cells. Carcinogenesis 2013; 35: 795-806
76. Matera L. Endocrine, paracrine and autocrine actions of prolactin on immune cells. Life Sci 1996; 59: 599-614
77. Clevenger CV, Freier DO, Kline JB. Prolactin receptor signal transduction in cells of the immune system. J Endocrinol 1998; 157: 187-97
78. Kooijman R, Gerlo S, Coppens A, Hooghe-Peters EL. Myeloid leukemic cells express and secrete bioactive pituitary-sized 23 kDa prolactin. J Neuroimmunol 2000; 110: 252-8
79. Langan EA, Foitzik-Lau K, Goffin V, et al. Prolactin: an emerging force along the cutaneous-endocrine axis. Trends Endocrinol Metab 2010; 21: 569-77
80. Ramot Y, Biro T, Tiede S, et al. Prolactin-a novel neuroendocrine regulator of human keratin expression in situ. FASEB J 2010; 24: 1768-79
81. Goldstein J, Fletcher S, Roth E, et al. Calcineurin/Nfatc1 signaling links skin stem cell quiescence to hormonal signaling during pregnancy and lactation. Genes Dev 2014; 28: 983-94
82. Langan EA, Ramot Y, Goffin V, et al. Mind the (gender) gap: does prolactin exert gender and/or site-specific effects on the human hair follicle? J Invest Dermatol 2010; 130: 886-91
83. Foitzik K, Krause K, Conrad F, et al. Human scalp hair follicles are both a target and a source of prolactin, which serves as an autocrine and/or paracrine promoter of apoptosis-driven hair follicle regression. Am J Pathol 2006; 168: 748-56
84. Lutz G. Hair loss and hyperprolactinemia in women. Dermatoendocrinology 2012; 4: 65-71
85. Lapointe TK, Altier C. The role of TRPA1 in visceral inflammation and pain. Channels (Austin) 2011; 5: 525-9
86. Vriens J, Appendino G, Nilius B. Pharmacology of vanilloid transient receptor potential cation channels. Mol Pharmacol 2009; 75: 1262-79
87. Noel GL, Suh HK, Stone JG, Frantz AG. Human prolactin and growth hormone release during surgery and other conditions of stress. J Clin Endocrinol Metab 1972; 35: 840-51
88. Patil MJ, Green DP, Henry MA, Akopian AN. Sex-dependent roles of prolactin and prolactin receptor in postoperative pain and hyperalgesia in mice. Neuroscience 2013; 253: 132-41
89. Bosco D, Belfiore A, Fava A, et al. Relationship between high prolactin levels and migraine attacks in patients with microprolactinoma. J Headache Pain 2008; 9: 103-7
90. Dev R, Hui D, Dalal S, et al. Association between serum cortisol and testosterone levels, opioid therapy, and symptom distress in patients with advanced cancer. J Pain Symptom Manage 2011; 41: 788-95
91. Patil MJ, Ruparel SB, Henry MA, Akopian AN. Prolactin regulates TRPV1, TRPA1, and TRPM8 in sensory neurons in a sex-dependent manner: Contribution of prolactin receptor to inflammatory pain. Am J Physiol Endocrinol Metab 2013; 305: E1154-64
92. Scotland PE, Patil M, Belugin S, et al. Endogenous prolactin generated during peripheral inflammation contributes to thermal hyperalgesia. Eur J Neurosci 2011; 34: 745-54
93. Diogenes A, Patwardhan AM, Jeske NA, et al. Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. J Neurosci 2006; 26: 8126-36
94. Shelly S, Boaz M, Orbach H. Prolactin and autoimmunity. Autoimmun Rev 2012; 11: A465-70
95. Dillner K, Kindblom J, Flores-Morales A, et al. Gene expression analysis of prostate hyperplasia in mice overexpressing the prolactin gene specifically in the prostate. Endocrinology 2003; 144: 4955-66
96. Orbach H, Zandman-Goddard G, Boaz M, et al. Prolactin and autoimmunity: hyperprolactinemia correlates with serositis and anemia in SLE patients. Clin Rev Allergy Immunol 2012; 42: 189-98
97. Stevens A, Ray DW, Worthington J, Davis JR. Polymorphisms of the human prolactin gene-implications for production of lymphocyte prolactin and systemic lupus erythematosus. Lupus 2001; 10: 676-83
98. Mellai M, Giordano M, DAlfonso S, et al. Prolactin and prolactin receptor gene polymorphisms in multiple sclerosis and systemic lupus erythematosus. Hum Immunol 2003; 64: 274-84
99. Leanos-Miranda A, Cardenas-Mondragon G, Rivera-Leanos R, et al. Application of new homologous in vitro bioassays for human lactogens to assess the actual bioactivity of human prolactin isoforms in hyperprolactinaemic patients. Clin Endocrinol (Oxf) 2006; 65: 146-53
100. Langan EA, Griffiths CE, Paus R. Exploring the role of prolactin in psoriasis. Arch Dermatol Res 2012; 304: 115-18
101. Reuwer AQ, Hoekstra M, Touraine P, et al. Is prolactin involved in the evolution of atherothrombic disease? Expert Rev Endocrinol Metab 2012; 7: 345-61
102. van der Sluis RJ, van den AT, Reuwer AQ, et al. Prolactin receptor antagonism uncouples lipids from atherosclerosis susceptibility. J Endocrinol 2014; 222: 341-50
103. El Chemaly S, Henske EP. Towards personalised therapy for lymphangioleiomyomatosis: lessons from cancer. Eur Respir Rev 2014; 23: 30-5
104. Terasaki Y, Yahiro K, Pacheco-Rodriguez G, et al. Effects of prolactin on TSC2-null Eker rat cells and in pulmonary lymphangioleiomyomatosis. Am J Respir Crit Care Med 2010; 182: 531-9
105. Sanati S, Watson MA, Salavaggione AL, Humphrey PA. Gene expression profiles of ductal versus acinar adenocarcinoma of the prostate. Mod Pathol 2009; 22: 1273-9
106. Broughton SE, Hercus TR, Lopez AF, Parker MW. Cytokine receptor activation at the cell surface. Curr Opin Struct Biol 2012; 22: 350-9
107. Goffin V, Hoang DT, Bogorad RL, Nevalainen MT. Prolactin regulation of the prostate gland: a female player in a male game. Nat Rev Urol 2011; 8: 597-607